论文部分内容阅读
兹将近几年来我们采用选择性肝动脉插管化疗(TAI)和栓塞(TAE)治疗中晚期肝癌的并发症分析如下。临床资料100例患者,男87例,女13例;年龄16～62岁,平均年龄45.6岁。全部病例均经临床检查证实为不能手术的中晚期肝癌,瘤体>10cm89例,其中54例>15cm。有不同程度的腹水、血浆白、球蛋白比例倒置者27例。治疗方法:采用Sildinger 法从股动脉插管,作选择性或超选择性推注血管造影,证实肝癌病变后,遂选用MMC10～20mg,CDDP80～100mg,5-Fu1000～1500mg 或ADM10mg化疗灌注,部分再与碘化油5～20ml 分次乳
In recent years, we have analyzed the complications of selective hepatic artery catheterization chemotherapy (TAI) and embolization (TAE) for the treatment of advanced liver cancer. Clinical data 100 patients, 87 males and 13 females; aged 16 to 62 years, mean age 45.6 years. All cases were confirmed by clinical examination as inoperable advanced liver cancer, tumor> 10cm 89 cases, 54 cases> 15cm. There were 27 cases with different degrees of inversion of ascites, plasma white and globulin. Treatment methods: Selective or superselective bolus angiography was performed with the use of the Sildinger method from the femoral artery to confirm that the liver cancer lesions were treated with MMC 10-20 mg, CDDP 80-100 mg, 5-Fu 1000-1500 mg, or ADM 10 mg chemotherapy perfusion. And then iodized oil 5 ~ 20ml fractionation